These Are The 10 Most Expensive Drugs In America

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Drugs, whether they are generic, OTC, or patented, are affordable to most Americans, particularly those who have healthcare that covers the cost of pharmaceuticals. However, in rare cases, drugs can cost hundreds of thousands of dollars a year when measured across a year of recommended treatment. Among the 10 most expensive drugs, not a single one is affordable by anyone who is not wealthy. Fortunately, many of these are also covered by insurance.

GoodRx, a company that provides mobile apps and PC-based products to track drug prices, has put together a list of the 10 most expensive drugs in America. Its researchers point out:

Many of the most expensive drugs are taken for an extended period of time, and costs quickly add up. This analysis ranks drugs by their annual cost for a typical course of therapy. Prices are based on the drug’s list price, which is the price that the pharmaceutical company assigns as an official price to a drug, then adjusted for time to create a comparable benchmark.

In each case, the cost of the drug over a year is well above $500,000

The GoodRx list:

Drug                      Manufacturer                      Annual cost
1 Zolgensma          AveXis, Inc                            $2,125,000
2 Zokinvy Eiger      BioPharmaceuticals              $1,032,480
3 Danyelza             Y-mAbs Therapeutics, Inc        $977,664
4 Myalept              Aegerion Pharmaceuticals        $889,904
5 Luxturna             Spark Therapeutics                    $850,000
6 Folotyn               Acrotech Biopharma                  $793,870
7 Brineura              BioMarin Pharmaceuticals         $730,340
8 Blincyto               Amgen, Inc                                $712,672
9 Ravicti                 Horizon Therapeutics                $695,970
10 Soliris                Alexion Pharmaceuticals, Inc     $678,392

Zolgensma is used to treat spinal muscular atrophy, according to GoodRx. Zokinvy is used to treat Hutchinson-Gilford progeria syndrome. Danyelza is used to treat neuroblastoma in bones. Myalept is used to treat leptin deficiency. Luxturna is used to treat retinal dystrophy. Folotyn is used to treat peripheral T-cell lymphoma. Brineura is used to treat Batten disease. Blincyto is used to treat acute lymphoblastic leukemia. Ravicti is used to treat urea cycle disorders. Soliris is used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Special thanks to GoodRx for the descriptions of the conditions treated by the 10 drugs.

Click here to see The 25 Most Dangerous Drugs In America

[wallst_email_signup]

 

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618